logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Q

Qingfu Zhang

the first hospital of china medical university
H指数:24
被引数:2,081

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression” [Eur. Urol. 76(2) (2019) 157–166]

勘误：“BHC80基因的RNA剪接促进神经内分泌前列腺癌进展”[Eur. Urol. 76(2) (2019) 157–166]

European Urology
IF25.2
2025-05-080
OA
Yinan Li; Ning Xie; Ruiqi Chen; Ahn R Lee; Jessica Lovnicki; Emma A Morrison; Ladan Fazli; Qingfu Zhang; Catherine A Musselman; Yuzhuo Wang; Jiaoti Huang; Martin E Gleave; Colin Collins; Xuesen Dong
Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China

中国多中心研究中乳腺癌患者历史评分与重新评分结果之间HER2-low和HER2-ultralow状态的患病率与一致性

BREAST CANCER RESEARCH
IF5.6
2025-03-250
OA
Lv, Hong; Yue, Junqiu; Zhang, Qingfu; Xu, Fangping; Gao, Peng; Yang, Haifeng; Nie, Xiu; Kong, Lingfei; Zhang, Guanjun; Li, Jianming; Xiao, Shiwei; Wu, Hongmei; Xing, Aiyan; Hong, Min; Fan, Jun; Guan, Huijuan; Cao, Peilong; Ni, Hengli; Yang, Wentao
Phase III study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort

Talazoparib (TALA) 联合 Enzalutamide (ENZA) 与 Placebo (PBO) 联合 ENZA 作为转移性去势抵抗性前列腺癌 (mCRPC) 患者的一线 (1L) 治疗的 III 期研究：TALAPRO-2 (TP-2) 中国队列

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Zeng, H.; Ye, D.; Guo, H.; Yang, Y.; Xue, B.; Zhang, X.; Xiao, W.; Jiang, J.; Sun, T.; Chen, W.; Wang, Y.; Wan, B.; He, D.; Zhang, Q.; Luo, H.; Wang, X.; Guo, J.; Ye, H.; Zhao, H.; Zhang, Y.
Capivasertib (C) plus fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2e advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort

Capivasertib (C) 联合氟维司群 (F) 治疗对芳香化酶抑制剂 (AI) 耐药的HR /HER2e晚期乳腺癌 (ABC) 患者 (pts): III期CAPItello-291试验中国队列

ANNALS OF ONCOLOGY
IF65.4
2023-11-010
PRE
Hu, X.; Zhang, Q.; Sun, T.; Xiong, H.; Li, W.; Teng, Y.; Lu, Y-S.; Tseng, L-M.; Yan, M.; Li, H.; Pang, D.; Chen, S. C.; Chen, W.; Jiang, O.; Wang, J.; Wu, X.; Fan, E.; Jiang, L.; Zeng, X.; Turner, N.

研究方向

暂未获取到该数据
J
Jiaoti Huang
H 指数:90论文数:732被引数:2.6万
X
Xueshan Qiu
H 指数:39论文数:186被引数:4,548
J
Jung Wook Park
H 指数:23论文数:45被引数:3,099
B
B. Smith
H 指数:29论文数:204被引数:3,758
S
Siyang Zhang
H 指数:22论文数:89被引数:1,392
张冠军 封面图
张冠军
H 指数:54论文数:820被引数:1.4万
M
Martin Gleave
H 指数:126论文数:1,832被引数:6.1万
I
Ivan Spasojević
H 指数:61论文数:378被引数:1.2万
E
Emmanuel S. Antonarakis
H 指数:82论文数:1,051被引数:3.5万
J
John K. Lee
H 指数:45论文数:293被引数:7,705